Trials / No Longer Available
No Longer AvailableNCT03414489
Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)
Expanded Access to ABC-108, A Phase IIA Study of ABC294640 in the Treatment of Patients With Advanced,Unresectable Intra-hepatic, Perihilar and Extra-Hepatic Cholangiocarcinoma
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- RedHill Biopharma Limited · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This is an expanded access program (EAP) for eligible participants who do not qualify for participation in, or who are otherwise unable to access, the ongoing clinical trial ABC-108. This program is designed to provide access to ABC294640 (Yeliva ®) for treatment of cholangiocarcinoma (CCA) prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. An oncologist must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Conditions
- Cholangiocarcinoma
- Cholangiocarcinoma Non-resectable
- Cholangiocarcinoma, Perihilar
- Cholangiocarcinoma, Extrahepatic
- Cholangiocarcinoma, Intrahepatic
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABC294640 |
Timeline
- First posted
- 2018-01-30
- Last updated
- 2025-03-18
Source: ClinicalTrials.gov record NCT03414489. Inclusion in this directory is not an endorsement.